ICO
Closed:

Seeking Research and Technologies Related to in vivo Direct Reprogramming

Astellas Pharma, a global pharmaceutical company with cutting-edge capabilities in drug development, wishes to engage with academic research and biopharma companies and assets that involve the use of in vivo direct reprogramming to achieve cell conversion/ transdifferentiation from one cell type to another functional type.

Astellas is particularly interested in the direct reprogramming of cells to cell types related to the Central Nervous System, Lung, Heart, Kidney, Liver, Gut, Skin and Eye. Their goal is to discover therapeutic interventions that cure...

Opportunity types being sought:

  • Technology

  • Academic Researcher

  • Centre of Excellence

  • Research Project

  • Spinout Company

  • Biotech Asset

To see the full details and submit your response please register now.

Benefits of registration:

  • Receive updates on the latest industry calls
  • Quickly and easily respond to calls via your dashboard
  • Build your academic profile

Opportunity types being sought:

  • Technology

  • Academic Researcher

  • Centre of Excellence

  • Research Project

  • Spinout Company

  • Biotech Asset

An online matchmaking platform for university-industry collaboration. Learn More

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.